MannKind Corporation (MNKD) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Study Overview: The ICoN-1 Phase 3 study, officially titled ICoN-1: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Clofazimine Inhalation Suspension When Added to Guideline-Based Therapy in Participants With Nontuberculous Mycobacterial Infection, was designed to assess the efficacy and safety of Clofazimine Inhalation Suspension. This study aimed to provide a new treatment option for patients with nontuberculous mycobacterial infections, a condition with limited effective therapies.
Intervention/Treatment: The study tested Clofazimine Inhalation Suspension, known as MNKD-101, an experimental drug delivered via inhalation to target lung infections directly. The treatment was compared to a placebo to evaluate its effectiveness when added to standard guideline-based therapy.
Study Design: This interventional study was randomized and used a parallel assignment model. Participants were randomly assigned to receive either the Clofazimine Inhalation Suspension or a placebo in a 2:1 ratio. The study was quadruple-masked, meaning the participant, care provider, investigator, and outcomes assessor were unaware of the treatment allocations. The primary purpose was treatment-focused.
Study Timeline: The study began on May 8, 2024, and was last updated on November 10, 2025. Unfortunately, the study was terminated, which means it did not reach its primary completion or estimated completion dates. These dates are crucial for tracking the study’s progress and understanding its current status.
Market Implications: The termination of this study could impact MannKind Corporation’s stock performance and investor sentiment, as the anticipated results will not materialize. Investors may need to reassess the company’s pipeline and potential revenue streams. Competitors in the pharmaceutical industry focusing on similar treatments may see this as an opportunity to advance their own research and development efforts.
The study is currently terminated, but further details can be found on the ClinicalTrials portal.
To learn more about MNKD’s potential, visit the MannKind Corporation drug pipeline page.